# Lilly (Eli)

**Source:** https://geo.sig.ai/brands/lilly-eli  
**Vertical:** Healthcare Tech  
**Subcategory:** Enterprise  
**Tier:** Leader  
**Website:** lilly.com  
**Last Updated:** 2026-04-14

## Summary

Indianapolis pharma leader (NYSE: LLY) $45.1B FY2024 revenue (+32%); Mounjaro $11.4B + Zepbound $4.9B tirzepatide GLP-1, oral orforglipron Phase 3, $18B manufacturing expansion competing with Novo Nordisk.

## Company Overview

Eli Lilly and Company is an Indianapolis, Indiana-based global pharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: LLY) as an S&P 500 Health Care component — discovering, developing, and commercializing medicines across diabetes, obesity, oncology, immunology, and neuroscience through approximately 43,000 employees worldwide. In fiscal year 2024, Eli Lilly reported revenues of $45.1 billion (+32% year-over-year) — driven by the historic commercial launch of Mounjaro (tirzepatide for type 2 diabetes, $11.4B revenue) and Zepbound (tirzepatide for obesity and obstructive sleep apnea, $4.9B revenue) — making Eli Lilly one of the fastest-growing large pharmaceutical companies in history and elevating its market capitalization above $700 billion at peak 2024 valuation, briefly making Lilly the most valuable healthcare company globally. CEO Dave Ricks' strategic investment in tirzepatide manufacturing capacity — committing $18+ billion to new US manufacturing sites in Indiana, Wisconsin, and North Carolina — reflects Lilly's execution of unprecedented pharmaceutical demand that has consistently outpaced supply since Mounjaro's 2022 approval and Zepbound's 2023 FDA approval for obesity. The GLP-1/GIP dual agonist mechanism (tirzepatide activates both GLP-1 and GIP incretin receptors, versus semaglutide's single GLP-1 activation) produces superior efficacy results — SURMOUNT-1 trial showing 22.5% average body weight loss with tirzepatide versus 15% with semaglutide (Ozempic/Wegovy) — establishing tirzepatide as the most effective approved obesity pharmacotherapy.

Eli Lilly's pharmaceutical innovation model creates competitive advantages through the tirzepatide franchise's superior clinical profile and pipeline depth across multiple GLP-1-adjacent mechanisms: while Novo Nordisk dominates the injectable semaglutide segment (Ozempic for diabetes, Wegovy for obesity), Lilly's tirzepatide delivered higher weight loss in head-to-head comparisons and secured additional indications (obstructive sleep apnea, heart failure with obesity — both FDA-approved in 2024) that create clinical differentiation beyond simple metabolic weight loss. The orforglipron program (oral GLP-1 receptor agonist pill, phase 3 trials showing 7-8% HbA1c reduction and 10% weight loss) represents the next clinical catalyst — an oral obesity treatment that eliminates the weekly injection barrier could dramatically expand the treatable population beyond the patients who self-inject semaglutide or tirzepatide. Lilly's oncology pipeline (Verzenio/abemaciclib for HR+ breast cancer, $4.2B revenue, growing as MONARCH trials expand indications) and immunology pipeline (mirikizumab for ulcerative colitis and Crohn's disease, lebrikizumab for atopic dermatitis) provide earnings diversification beyond the GLP-1 franchise.

In 2025, Eli Lilly competes in GLP-1 diabetes/obesity therapeutics, oncology, and immunology against Novo Nordisk (CPH: NOVO B, Ozempic and Wegovy semaglutide, global GLP-1 leader by market share), AstraZeneca (LON: AZN, oncology and cardiovascular), and Pfizer (NYSE: PFE, oncology and vaccines) for diabetes and obesity drug market share, oncology IO and CDK4/6 inhibitor competition, and global pharmaceutical distribution. The supply constraint environment for tirzepatide (FDA shortage designation for Zepbound and Mounjaro through most of 2024) has eased as Lilly's manufacturing expansion comes online — new capacity from Lilly's $18B manufacturing investment reduces supply shortages that limited revenue growth in 2024 below demand levels. The orforglipron oral GLP-1 Phase 3 data (expected late 2025/2026) represents the defining competitive event for the obesity treatment market: an effective oral pill would capture patients who refuse injections and expand the treatable obesity population by hundreds of millions globally. The 2025 strategy focuses on tirzepatide supply expansion (filling unmet demand as manufacturing capacity increases), oral GLP-1 clinical program advancement, and Verzenio breast cancer market share growth against CDK4/6 competitors Pfizer's Ibrance and Novartis's Kisqali.

## Frequently Asked Questions

### What does Eli Lilly do?
Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures, and markets innovative medicines for serious health conditions. The company focuses on diabetes, obesity, oncology, immunology, neuroscience (including Alzheimer's disease), and cardiometabolic diseases. Lilly's portfolio includes breakthrough treatments like Mounjaro and Zepbound for diabetes and obesity, Verzenio for breast cancer, Kisunla for Alzheimer's disease, and a century-long legacy of insulin products.

### When was Eli Lilly founded?
Eli Lilly and Company was founded on May 10, 1876, by Colonel Eli Lilly, a pharmaceutical chemist and Union Army veteran of the Civil War. The company started in Indianapolis, Indiana, with $1,400 in working capital and three employees. It has been operating for nearly 150 years and has remained headquartered in Indianapolis throughout its history.

### Where is Eli Lilly headquartered?
Eli Lilly is headquartered in Indianapolis, Indiana, United States, where it has been located since its founding in 1876. The company operates globally with offices in 18 countries and products sold in approximately 125 countries worldwide, making it one of Indiana's most important corporate citizens and a global pharmaceutical leader.

### Who are Eli Lilly's primary customers and target markets?
Lilly serves patients worldwide suffering from diabetes, obesity, cancer, Alzheimer's disease, autoimmune conditions, and cardiovascular diseases. The company's customers include healthcare providers, hospitals, pharmacy benefit managers, insurance companies, government health programs, and ultimately the millions of patients who depend on Lilly medicines. Products are distributed globally through both commercial channels and patient assistance programs.

### What are Eli Lilly's breakthrough products driving recent growth?
Lilly's growth is primarily driven by tirzepatide products: Mounjaro for type 2 diabetes ($11.54B in 2024 sales) and Zepbound for obesity ($4.9B in 2024). Other key products include Verzenio for breast cancer (12% of 2024 revenues), Humalog insulin (5% of revenues), newly launched Kisunla for Alzheimer's disease, Jardiance for diabetes and cardiovascular health, and Taltz for autoimmune diseases. Together, these represent 37% of 2024 revenues from incretin medicines alone.

### What makes Eli Lilly different from competitors?
Lilly differentiates itself through 150 years of pharmaceutical innovation heritage, first-to-market breakthrough therapies (first commercial insulin in 1923, Prozac for depression in 1988, market-leading GLP-1 therapies), achievement as the first $1 trillion healthcare company, industry-leading gross margins of 83.2%, significant R&D investment (11,436 employees or 22.8% of workforce), strong pipeline across multiple therapeutic areas, and commitment to access (such as the $35 insulin price cap).

### Who are Eli Lilly's main competitors?
Lilly competes with major pharmaceutical companies including Novo Nordisk (direct competitor in diabetes and obesity with Ozempic and Wegovy), Pfizer, Johnson & Johnson, Merck, AstraZeneca, Novartis, Roche, Bristol Myers Squibb, AbbVie, and Amgen. In the rapidly growing GLP-1 market for obesity and diabetes, Novo Nordisk is the primary competitor, though Lilly's tirzepatide has demonstrated superior efficacy in head-to-head trials.

### How has Eli Lilly performed financially in 2024?
Lilly achieved exceptional 2024 performance with revenue of $45.04 billion (up 32% from 2023), Q4 revenue of $13.53 billion (up 45%), Q4 net income of $4.41 billion with EPS of $4.88, gross margin of 83.2%, and achievement of $1 trillion market capitalization in November 2025. For 2025, Lilly projects revenue between $58.0-61.0 billion, representing continued 32% growth.

### What is Eli Lilly's approach to sustainability and diversity?
Lilly demonstrates strong ESG commitments through environmental sustainability goals to reduce emissions and waste, responsible water usage across operations, improved diversity with women in management increasing from 41% to over 49% (2017-2022), minority representation in U.S. management growing from 16% to nearly 25%, inclusive culture fostered through employee resource groups, and continuous improvement in environmental impact across product life cycles and supply chain.

### How can I contact Eli Lilly?
Visit the official website at www.lilly.com for product information, patient resources, and healthcare provider materials. For investor relations, visit investor.lilly.com. The corporate headquarters is located in Indianapolis, Indiana. Patients can access medicines through healthcare providers, pharmacies, and Lilly's patient assistance programs. The company maintains regional offices across 18 countries globally.

### Is Eli Lilly hiring?
Yes, Eli Lilly employs 47,000 people globally, including 11,436 in research and development (22.8% of workforce). The company regularly seeks talent across scientific research, clinical development, manufacturing, commercial operations, finance, legal, and corporate functions. Career opportunities span locations worldwide, with significant presence in Indianapolis and global hubs. Visit Lilly's careers website for current openings.

### What are Eli Lilly's recent major developments and future plans?
Recent developments include achieving $1 trillion market cap (first healthcare company, November 2025), record 2024 revenue of $45B driven by Mounjaro and Zepbound, Kisunla Alzheimer's drug approval (2024), acquisition of Scorpion Therapeutics for $2.5B (breast cancer pipeline), acquisition of Adverum Biotechnologies (gene therapy for vision loss), and ambitious 2025 guidance of $58-61B revenue. The company continues expanding its obesity, diabetes, oncology, and neuroscience pipelines with multiple Phase 3 candidates.

## Tags

b2b, healthtech, manufacturing, saas, public

---
*Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*